MA-ASPECT
29.7.2020 15:02:13 CEST | Business Wire | Press release
Today, Aspect announced the general availability of Aspect® Unified IP® and Advanced List Management™ 7.4 SP1, the latest release of its comprehensive, omnichannel customer engagement platform for managing experiences across service, collections and sales. This upgrade provides major enhancements in usability to deliver a modern user experience, making it easier to use for agents, managers and administrators use. The 7.4 SP1 release also builds upon Aspect’s outbound market leadership by adding new capabilities to help customers operate outbound contact centers efficiently, effectively and in compliance with national, regional and local regulations.
“Aspect Unified IP is the premier inbound and outbound enterprise contact center solution available in the market, and has been for over 14 years. The world’s top brands depend on Unified IP every day, and we are committed to continued development and offering new capabilities to help companies build lifetime loyalty among their consumers,” said Michael Harris, Chief Product Officer and CMO at Aspect.
Aspect Unified IP and Advanced List Management deliver advanced customer engagement capabilities that drive profitability and customer loyalty for many of the largest enterprises in financial, communications, retail, healthcare, and customer service around the world. Aspect remains committed to building upon and maintaining this essential platform. This release features improvements to the user interface such as:
- Improves the user interface for agents, managers and administrators into a consolidated, intuitive design across a variety of functions
- Provides managers, supervisors and administrators an improved user experience with quicker access to configuration tools, real-time data and alerts
- Refreshing third party tech so customers can stay current with security, compliance and IT protocols
“Aspect Unified IP provides best-in-class functionality and uptime for our entire organization including collections, customer service, back office, loan origination, and service desk. It is both an effective and efficient solution for our contact center and customer engagement needs,” said Michael Montgomery, VP Contact Center Solutions Exeter Finance
In the face of a global recession, the importance of outbound dialing and collections will steadily rise across industries. Aspect offers the only comprehensive outbound contact center solutions that allow the world’s largest organizations to effectively conduct proactive outreach activities while maintaining compliance with complicated regional, local, and national regulatory requirements. Aspect Unified IP and Advanced List Management are well equipped to help organizations adapt to the new challenges posed by this recession, and with the 7.4 SP1 release, additional capabilities have been added to ALM’s extensive tool set such as:
- Functionality to help improve operational efficiency, allowing organizations to smooth out dialing and reach more customers in a shorter period of time
- Goal-driven rules to ensure dialing aligns with an overall outreach strategy
- Security and auditing features to help maintain compliance with relevant regulations
- The ability to play specific messages for each attempt, creating more effective customer experiences while improving operational efficiency by minimizing repeat interactions
“City of Mesa has been on the Aspect Unified IP platform for six-plus years now since upgrading from legacy Aspect CallCenter® ACD. Like its predecessor, it has been a rock solid/stable platform in support of both standard hours and 24x7 services. The ease of being able to stand up new departments on the platform for remote workers during this time has proven to be invaluable,” said Richard Sandoval, Senior Unified Communications Engineer City of Mesa.
FIND OUT MORE about Aspect Unified IP and Advanced List Management.
About Aspect
Aspect is on a mission to simplify and improve customer engagement. Our enterprise software is used by millions of agents every year and supports billions of consumer interactions around the world. Our best-of-breed contact center and workforce optimization applications help companies keep agents engaged while providing exceptional customer service experiences. Our flexible, highly scalable solutions for self-service and live interaction management and workforce optimization are available on-premises or in any hosted, private or public cloud environment.
For more information, visit www.aspect.com . Follow Aspect on Twitter at @AspectSoftware. Read our blogs at http://blogs.aspect.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200729005568/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom